Study Of C-KIT Mutations In Familial Gastrointestinal Stromal Tumours, Melanoma And A Novel Form Of Waardenburg Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$68,378.00
Summary
The primary aim of this research project is to study mutations in a cancer causing gene called c-KIT. We seek to identify tumour characteristics which are predictive for the presence of particular types of c-KIT mutations in melanomas and gastrointestinal stromal tumours. The detection of tumours harbouring these mutations will help in the treatment of cancer sufferers because this group of patients have been shown to respond very well to a class of drugs known as tyrosine kinase inhibitors.
The Role Of The Human RECK Protein In Modifying Human Sarcoma Progression Within In Vitro And In Vivo Models
Funder
National Health and Medical Research Council
Funding Amount
$34,878.00
Summary
The protein “RECK” is known to have a controlling effect on cancers by reducing growth, invasion, and blood supply. RECK is present in normal tissues but in bone and soft-tissue tumours (sarcomas), the protein is reduced. This study aims to; correlate RECK levels in sarcoma with patient survival, use gene technology to increase RECK levels in sarcoma cells, and observe the effects on sarcoma invasion and metastasis.
Identification Of Biomarkers Predictive Of Response To Bevacizumab In Patients With Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$32,628.00
Summary
Despite multimodality therapy, the median survival for patients diagnosed with high grade malignant brain tumours is only 12 months. Patient response to therapy is highly variable. Our aim is to develop a “genetic signature” that will predict response to bevacuzimab (an agent targeting blood vessel formation). Identifying patients who will respond to bevacuzimab will save many patients from a toxic and costly therapy, from which they will derive little benefit.